Briefly about FIT Biotech

FIT Biotech is a biotechnology company founded in 1995. The company develops and licenses its patented GTU® (Gene Transport Unit) vector technology for new-generation medical treatments. GTU® is a gene transport technology that provides a solution to a significant medical challenge in gene therapy and DNA vaccines.

Based on the studies presented by the company, both the Food and Drug Administration (FDA) in the United States and the European Medicines Agency have found the operating principle of the technology safe.

At present, FIT Biotech is applying its GTU® technology to seven drug development projects, with applications such as cancer (gene therapy), infectious diseases such as HIV and tuberculosis, as well as animal vaccines.

FIT Biotech shares are listed on the First North Finland market maintained by NASDAQ OMX Helsinki Oy.